NeuroImage-Clinical is a premier open access journal published by Elsevier Science Ltd, dedicated to advancing the field of clinical neuroimaging and its applications in a variety of neurological disorders. With an ISSN of 2213-1582, this journal has established itself as a leading source of innovative research since its inception in 2012, now continuing through 2024. Recognized for its high impact, it occupies the top quartile (Q1) in prestigious categories such as Cognitive Neuroscience, Neurology, and Radiology, affirming its relevance in clinical and research settings. Its Scopus rankings further exemplify its significant contribution to the disciplines of Radiology and Neurology, consistently placing it among the top tiers of journals in these fields. This journal not only provides critical insights for researchers and professionals but also serves as a valuable resource for students, fostering an understanding of the complexities in neuroimaging techniques and their implications for patient care. With open access options ensuring broad dissemination of knowledge, NeuroImage-Clinical plays a pivotal role in enhancing collaboration and innovation within the global neuroscience community.

Frontiers in Aging Neuroscience, published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to the field of aging neuroscience, with its ISSN being 1663-4365. Since its inception in 2009, this journal has provided a platform for researchers to disseminate their findings on the neurological aspects of aging, addressing critical issues that impact cognition and overall brain health in the elderly population. With a commendable 2023 impact factor, the journal ranks in the Q2 category in both Aging and Cognitive Neuroscience, positioning it among the top-tier publications in these fields. Notably, it is recognized within Scopus, ranking #32 out of 115 in Neuroscience (Cognitive Neuroscience) and #20 out of 38 in the Aging sector, with corresponding percentiles of 72nd and 48th, respectively. As an open-access journal, it promotes unrestricted access to research findings, fostering collaboration and innovation among the academic community. Researchers, professionals, and students alike can explore cutting-edge studies that contribute to understanding the complexities of neurological aging and work towards improving cognitive health in an aging society.

Translational Neurodegeneration, an esteemed journal in the field of neuroscience, is published by BMC and has been an open access platform since 2012, delivering high-quality research from its base in the United Kingdom. With an impressive impact factor reflecting its significant contributions, this journal focuses on critical advancements in cellular and molecular neuroscience, cognitive neuroscience, and clinical neurology, boasting a Q1 ranking across all these categories as of 2023. Researchers and professionals benefit from its extensive reach, characterized by exceptional Scopus rankings that place it in the top percentile of its field. The journal serves as a vital resource for academics and healthcare practitioners alike, aiming to bridge the gap between laboratory discoveries and clinical applications, thereby enhancing understanding and treatment of neurodegenerative diseases. With its commitment to open access, Translational Neurodegeneration ensures that its published research is accessible to a global audience, promoting collaboration and knowledge exchange within the scientific community.

Degenerative Neurological and Neuromuscular Disease is a distinguished academic journal published by DOVE MEDICAL PRESS LTD, focusing on the latest advancements in the field of neurology and neuromuscular disorders. With a commitment to disseminating high-quality research, the journal aims to provide a critical platform for researchers, healthcare professionals, and students to share and engage with groundbreaking studies that advance our understanding of degenerative conditions affecting the nervous system. Although the journal's impact factor and h-index are currently not available, its open access model ensures that the valuable findings published within are accessible to a global audience, thereby fostering collaboration and innovation in neurological health. The journal's address is PO BOX 300-008, Albany, Auckland 0752, New Zealand, reflecting its international relevance and commitment to advancing the field of neurology. As the understanding of neurodegenerative diseases and neuromuscular challenges continues to evolve, Degenerative Neurological and Neuromuscular Disease serves as an essential resource for anyone dedicated to improving patient outcomes and advancing scientific knowledge.

NEUROLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal in the field of neurology, holding an esteemed Q1 category ranking in clinical neurology as of 2023. Established in 1951, this journal has been a critical resource for the dissemination of cutting-edge research and clinical advancements, with an impressive Scopus rank of 24 out of 400, placing it in the 94th percentile among its peers. NEUROLOGY serves as a vital platform for neurologists, researchers, and medical professionals seeking to stay abreast of the latest findings and innovations in the treatment and understanding of neurological disorders. With its rigorous peer-review process and commitment to excellence, NEUROLOGY remains essential reading for all individuals dedicated to advancing the science and practice of neurology, contributing significantly to the ongoing dialogue in this vital area of medicine.

Canadian Journal of Neurological Sciences, published by Cambridge University Press, stands as a reputable source of knowledge in the field of neurology, dedicated to advancing research and clinical practice. With an ISSN of 0317-1671 and an E-ISSN of 2057-0155, this journal has been a cornerstone for the exchange of ideas since its inception in 1974 and will continue to cater to the academic community until 2024. Recognized in the top quartile (Q2) in various categories including Medicine (miscellaneous) and Neurology (clinical), its articles engage a broad audience, ranging from established researchers to students seeking to deepen their understanding of neurological sciences. Although the journal is not an open-access publication, it provides vital insights and research findings that contribute significantly to its fields. With a Scopus rank of #183 in clinical neurology and a percentile ranking that reflects its commendable standing, the Canadian Journal of Neurological Sciences is indispensable for those committed to the exploration and treatment of neurological disorders.

NEUROCHEMISTRY INTERNATIONAL, published by Pergamon-Elsevier Science Ltd, offers a premier platform for researchers and professionals in the realms of cell biology and cellular and molecular neuroscience. Established in 1980 and continuing its passion for advancing the field, this esteemed journal enhances scientific collaboration with a notable 2023 Q2 ranking in both relevant categories, placing it among the top-tier publications in its discipline with a Scopus rank of 23/97 for Cellular and Molecular Neuroscience. With its focus on groundbreaking research, the journal provides a wealth of vital data and insights that drive forward our understanding of neurochemistry and its implications in health and disease. While not an Open Access journal, NEUROCHEMISTRY INTERNATIONAL is integral for professionals, academics, and students aiming to stay at the forefront of neurobiological research innovations, making significant contributions to both academia and clinical applications.

European Neurology, published by KARGER, is a distinguished journal in the field of neurology, catering to both clinical and neuroscience specialties. Since its inception in 1897 and continuing through 2024, the journal has been a vital platform for disseminating significant research findings and insights in neurology. With an ISSN of 0014-3022 and E-ISSN of 1421-9913, it ranks in the Q3 quartile in both clinical neurology and general neurology categories, reflecting its commitment to scholarly excellence while holding the 175th rank in clinical medicine and the 93rd in neuroscience, according to Scopus metrics. European Neurology facilitates a deeper understanding of neurological disorders and treatments, appealing to a diverse readership that includes researchers, clinicians, and students alike. Despite not currently offering open access, the journal’s rigorous peer-review process ensures that only high-quality research reaches its audience, making it an essential resource for those looking to stay informed in the rapidly evolving field of neurology.

FOLIA NEUROPATHOLOGICA is a distinguished Open Access journal specializing in the fields of Neurology and Pathology, published by the reputable TERMEDIA PUBLISHING HOUSE LTD. With an ISSN of 1641-4640 and E-ISSN 1509-572X, this journal has been a vital resource for the dissemination of high-quality research since its inception in 1994. Covering a broad spectrum of topics within neuropathology, the journal emphasizes clinical findings and forensic implications, making it an essential platform for healthcare professionals, researchers, and students alike. With impressive impact factors positioning it in the Q3 category for both Neurology (clinical) and Pathology and Forensic Medicine, FOLIA NEUROPATHOLOGICA occupies a significant place among its peers, ranked within the 36th to 46th percentiles on Scopus. Scholars can benefit from the Open Access model implemented since 2005, ensuring wide accessibility and distribution of critical research outputs aimed at advancing both clinical practices and academic knowledge. Based in Poland, at KLEEBERGA 2, POZNAN 61-615, this journal continues to shape the discourse in neuropathology and related fields.

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.